Skip to Main Content

More than four months after promising to resign from biotech’s most powerful hedge fund, Sam Isaly has stepped down from OrbiMed Advisors in the wake of allegations of rampant sexual harassment.

Isaly, 73, has transferred his control of the $14 billion fund to three of the firm’s partners, OrbiMed said in a statement. Sven Borho, Carl Gordon, and Jonathan Silverstein will lead OrbiMed from now on, the firm said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.